1. Scrip
  2. >>Archive

Merck's Stellar Keytruda Squamous Lung Cancer Data Refute Naysayers

 
• By Emily Hayes

In Phase III KEYNOTE-407 of squamous NSCLC, Keytruda/chemo combo shows overall survival benefit, which was reassuring news for doctors – and investors – ahead of ASCO.

Merck & Co. Inc.'s announcement that its PD-1 inhibitor Keytruda combined with chemotherapy demonstrated overall survival and progression-free survival benefits in the KEYNOTE-407 study in first-line squamous non-small lung cancer (NSCLC) support the drug's role in this indication and dominance in the tumor type generally.

Merck announced May 23 that the combination of Keytruda (pembrolizumab) and chemo demonstrated benefits for the co-primary endpoints of progression-free survival (PFS) and overall survival (OS) versus chemotherapy alone in an interim analysis of the KEYNOTE-407 study, which enrolled 560 patients with the metastatic

More from Archive

More from Scrip

In Brief: Genmab To Seek FDA Nod For Epkinly In Lymphoma

 
• By Sushmita Panda

Genmab will submit an sBLA for Epkinly in R/R follicular lymphoma in H1 2025, backed by positive Phase III data.

Pharma Predicts Modest Impact From Tariffs, But It Depends On What Comes Next

 
• By Jessica Merrill

Drugmakers aren’t expecting a big financial hit from tariffs for now, but a report commissioned by PhRMA suggests the cost of pharma-sector tariffs could be steep.

OPPI’s Matai On Section 3(d) Of India’s Patent Regulations: Now’s The Time To Open Up

 
• By Anju Ghangurde

Anil Matai, director general, Organization of Pharmaceutical Producers of India, talks in this audio interview about the evolving intellectual property landscape in India post the 2024 amendments, including long-standing sticking points such as Section 3(d) of India’s patent regulations and innovator firms' experience of the Bolar provision. There’s also a "compelling reason" to consider regulatory data protection, he claims.